ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $2.39M invested in ProShares UltraShort NASDAQ Biotechnology in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and closing their positions.
27% more capital invested
Capital invested by funds: $1.88M → $2.39M (+$511K)
14% more funds holding
Funds holding: 7 → 8 (+1)
1.33% more ownership
Funds ownership: 9.77% → 11.1% (+1.3%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$685K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$224K |
| 3 |
IMC Chicago
Chicago,
Illinois
|
+$65.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$473K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$174K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$27.1K |
| 4 |
Morgan Stanley
New York
|
-$3.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $943K | +$685K | +12,250 | +234% |
|
|
2
IMC Chicago
Chicago,
Illinois
| $566K | +$65.4K | +1,168 | +13% |
|
|
OMC
3
Old Mission Capital
Chicago,
Illinois
| $413K | -$473K | -8,447 | -52% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $241K | -$174K | -3,116 | -41% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $216K | +$224K | +4,001 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $11K | -$27.1K | -485 | -71% |
|
|
7
Morgan Stanley
New York
| $2K | -$3.02K | -54 | -59% |
|
8
Citigroup
New York
| $2K | – | – | – |
|
BIS Hedge Fund Activity: Q2 2022 in Review
8 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2022, worth a combined $2.39M — up 27% from $1.88M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BIS positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $685K. The largest seller was Old Mission Capital, cutting an estimated $473K.
- 8 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2022, up from 7 in Q1 2022.
- Funds reported $2.39M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2022, up 27% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2022 was Citadel Advisors, an estimated $685K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2022 was Old Mission Capital, an estimated $473K sold.
Based on aggregated 13F filings for Q2 2022.